264271-62-7

Upstream product

• 264271-57-0 methyl (αS,3S)-13-azido-α-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methyl]-12-oxo-1,6-dioxa-11-azadispiro[4.2.6.2]hexadecane-11-acetate 
• 264271-71-8 Formic acid (S)-2-((S)-3-formylamino-9,14-dioxa-1-aza-dispiro[4.2.6.2]hexadec-1-yl)-3-[4-(3-methyl-but-2-enyloxy)-phenyl]-propyl ester 
• 264271-70-7 (S)-2-((S)-3-Amino-9,14-dioxa-1-aza-dispiro[4.2.6.2]hexadec-1-yl)-3-[4-(3-methyl-but-2-enyloxy)-phenyl]-propan-1-ol 
• 264271-58-1 (S)-2-((S)-3-Methylamino-9,14-dioxa-1-aza-dispiro[4.2.6.2]hexadec-1-yl)-3-[4-(3-methyl-but-2-enyloxy)-phenyl]-propan-1-ol 
• 264271-60-5 (5S)-4-methyl-2-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methyl]-dispiro[1,4-diazabicyclo[3.2.1]oct[2]en-7,1'-cyclohexane-4',2-[1,3]dioxepane] 
• 264271-61-6 C₂₈H₃₉N₂O₃⁽¹⁺⁾ 

Downstream Products

• 244239-39-2 (1'S,2'Z,5'S)-4'-methyl-2'-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methylene]-spiro[cyclohexane-1,7'-[1,4]diazabicyclo[3.2.1]octan]-4-one 

Relevant academic research and scientific papers

Biomimetic total syntheses of (-)-TAN1251A, (+)-TAN1251B, (+)-TAN1251C, and (+)-TAN1251D

(equation presented) The muscarinic antagonists (-)-TAN1251A (1), (+)-TAN1251B (2), (+)-TAN1251C (3), and (+)-TAN1251D (4) have been synthesized biomimetically by enamine formation from an amino aldehyde to give TAN1251C ketal 18. Oxidation and reduction lead to TAN1251A (1), which has been hydroxylated to give TAN1251B (2). Stereospecific reduction of TAN1251C ketal 18 leads to TAN1251D (4).